By: Benzinga
UPDATE: Wedbush Upgrades Ironwood Pharmaceuticals to Neutral on LINZESS Strength
Wedbush upgraded Ironwood Pharmaceuticals (NASDAQ: IRWD ) from Underperform to Neutral and raised the price target from $11.00 to $13.00. Wedbush said, "Early script data for Q1:13 (5 weeks) suggests strong week-over-week LINZESS performance (20,000+ pills per week growth), which, if sustained, would see Q1 and FY:13 end-user demand well
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here